Abstract
The relationship between dopamine (DA) tone in the prefrontal cortex (PFC) and PFC-dependent cognitive functions (for example, working memory, selective attention, executive function) may be described by an inverted-U-shaped function, in which both excessively high and low DA is associated with impairment. In the PFC, the COMT val158met single nucleotide polymorphism (rs4680) confers differences in catechol-O-methyltransferase (COMT) efficacy and DA tone, and individuals homozygous for the val allele display significantly reduced cortical DA. Many studies have investigated whether val158met genotype moderates the effects of dopaminergic drugs on PFC-dependent cognitive functions. A review of 25 such studies suggests evidence for this pharmacogenetic effect is mixed for stimulants and COMT inhibitors, which have greater effects on D1 receptors, and strong for antipsychotics, which have greater effects on D2 receptors. Overall, COMT val158met genotype represents an enticing target for identifying individuals who are more likely to respond positively to dopaminergic drugs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Beaulieu JM, Gainetdinov RR . The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011; 63: 182–217.
Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 2000; 408: 199–203.
De Mei C, Ramos M, Iitaka C, Borrelli E . Getting specialized: presynaptic and postsynaptic dopamine D2 receptors. Curr Opin Pharmacol 2009; 9: 53–58.
Lidow MS, Goldman-Rakic PS, Gallager DW, Rakic P . Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390. Neuroscience 1991; 40: 657–671.
Durstewitz D, Seamans JK . The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia. Biol Psychiatry 2008; 64: 739–749.
Cropley VL, Fujita M, Innis RB, Nathan PJ . Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry 2006; 59: 898–907.
Haber SN . The place of dopamine in the cortico-basal ganglia circuit. Neuroscience 2014; 282C: 248–257.
Dreyer JK, Herrik KF, Berg RW, Hounsgaard JD . Influence of phasic and tonic dopamine release on receptor activation. J Neurosci 2010; 30: 14273–14283.
Cools R, D'Esposito M . Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry 2011; 69: e113–e125.
Arnsten AF . Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 1997; 11: 151–162.
Goldman-Rakic PS, Muly EC 3rd, Williams GV . D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 2000; 31: 295–301.
Zahrt J, Taylor JR, Mathew RG, Arnsten AF . Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 1997; 17: 8528–8535.
Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI . Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 1998; 18: 2697–2708.
Matsumoto M, Weickert CS, Akil M, Lipska BK, Hyde TM, Herman MM et al. Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience 2003; 116: 127–137.
Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM . Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6: 243–250.
Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004; 75: 807–821.
Slifstein M, Kolachana B, Simpson EH, Tabares P, Cheng B, Duvall M et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol Psychiatry 2008; 13: 821–827.
Craddock N, Owen MJ, O'Donovan MC . The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons. Mol Psychiatry 2006; 11: 446–458.
Lachman HM . Does COMT val158met affect behavioral phenotypes: yes, no, maybe? Neuropsychopharmacology 2008; 33: 3027–3029.
Grace AA . Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991; 41: 1–24.
Arnsten AF . Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009; 23: 33–41.
Cheuk DK, Wong V . Meta-analysis of association between a catechol-O-methyltransferase gene polymorphism and attention deficit hyperactivity disorder. Behav Genet 2006; 36: 651–659.
Munafo MR, Bowes L, Clark TG, Flint J . Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies. Mol Psychiatry 2005; 10: 765–770.
Rosa A, Peralta V, Cuesta MJ, Zarzuela A, Serrano F, Martinez-Larrea A et al. New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am J Psychiatry 2004; 161: 1110–1112.
Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D . A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002; 159: 652–654.
Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 2003; 60: 889–896.
Barnett JH, Scoriels L, Munafo MR . Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry 2008; 64: 137–144.
Witte AV, Floel A . Effects of COMT polymorphisms on brain function and behavior in health and disease. Brain Res Bull 2012; 88: 418–428.
Robbins TW, Arnsten AF . The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci 2009; 32: 267–287.
Gelernter J . Genetics of complex traits in psychiatry. Biol Psychiatry 2015; 77: 36–42.
Muller U, von Cramon DY, Pollmann S . D1- versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci 1998; 18: 2720–2728.
Narayanan NS, Land BB, Solder JE, Deisseroth K, DiLeone RJ . Prefrontal D1 dopamine signaling is required for temporal control. Proc Natl Acad Sci USA 2012; 109: 20726–20731.
Chudasama Y, Robbins TW . Dopaminergic modulation of visual attention and working memory in the rodent prefrontal cortex. Neuropsychopharmacology 2004; 29: 1628–1636.
Sawaguchi T, Goldman-Rakic PS . D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 1991; 251: 947–950.
Dodds CM, Clark L, Dove A, Regenthal R, Baumann F, Bullmore E et al. The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD signal during the manipulation of information in working memory. Psychopharmacology (Berl) 2009; 207: 35–45.
Mehta MA, Manes FF, Magnolfi G, Sahakian BJ, Robbins TW . Impaired set-shifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers. Psychopharmacology (Berl) 2004; 176: 331–342.
la Fougere C, Meisenzahl E, Schmitt G, Stauss J, Frodl T, Tatsch K et al. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study. J Nucl Med 2005; 46: 1028–1033.
Bitsios P, Roussos P . Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia. Pharmacogenomics 2011; 12: 559–566.
Llerena A, Berecz R, Penas-Lledo E, Suveges A, Farinas H . Pharmacogenetics of clinical response to risperidone. Pharmacogenomics 2013; 14: 177–194.
Diaz-Asper CM, Weinberger DR, Goldberg TE . Catechol-O-methyltransferase polymorphisms and some implications for cognitive therapeutics. NeuroRx 2006; 3: 97–105.
Berridge CW, Arnsten AF . Psychostimulants and motivated behavior: arousal and cognition. Neurosci Biobehav Rev 2013; 37: 1976–1984.
Gamo NJ, Wang M, Arnsten AF . Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry 2010; 49: 1011–1023.
Hakkarainen JJ, Jalkanen AJ, Kaariainen TM, Keski-Rahkonen P, Venalainen T, Hokkanen J et al. Comparison of in vitro cell models in predicting in vivo brain entry of drugs. Int J Pharm 2010; 402: 27–36.
Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 2003; 100: 6186–6191.
Hamidovic A, Dlugos A, Palmer AA, de Wit H . Catechol-O-methyltransferase val158met genotype modulates sustained attention in both the drug-free state and in response to amphetamine. Psychiatr Genet 2010; 20: 85–92.
Hart AB, de Wit H, Palmer AA . Candidate gene studies of a promising intermediate phenotype: failure to replicate. Neuropsychopharmacology 2013; 38: 802–816.
Wardle MC, Hart AB, Palmer AA, de Wit H . Does COMT genotype influence the effects of d-amphetamine on executive functioning? Genes Brain Behav 2013; 12: 13–20.
Cheon KA, Jun JY, Cho DY . Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder. Int Clin Psychopharmacol 2008; 23: 291–298.
Froehlich TE, Epstein JN, Nick TG, Melguizo Castro MS, Stein MA, Brinkman WB et al. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011; 50: 1129–39 e2.
Kereszturi E, Tarnok Z, Bognar E, Lakatos K, Farkas L, Gadoros J et al. Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1431–1435.
Park S, Kim JW, Kim BN, Shin MS, Yoo HJ, Cho SC . Catechol-O-methyltransferase Val158-Met polymorphism and a response of hyperactive-impulsive symptoms to methylphenidate: A replication study from South Korea. J Psychopharmacol 2014; 28: 671–676.
McGough JJ, McCracken JT, Loo SK, Manganiello M, Leung MC, Tietjens JR et al. A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2009; 48: 1155–1164.
Sengupta S, Grizenko N, Schmitz N, Schwartz G, Bellingham J, Polotskaia A et al. COMT Val108/158Met polymorphism and the modulation of task-oriented behavior in children with ADHD. Neuropsychopharmacology 2008; 33: 3069–3077.
Salatino-Oliveira A, Genro JP, Zeni C, Polanczyk GV, Chazan R, Guimaraes AP et al. Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder. Biol Psychiatry 2011; 70: 216–221.
Contini V, Victor MM, Bertuzzi GP, Salgado CA, Picon FA, Grevet EH et al. No significant association between genetic variants in 7 candidate genes and response to methylphenidate treatment in adult patients with ADHD. J Clin Psychopharmacol 2012; 32: 820–823.
McCracken JT, Badashova KK, Posey DJ, Aman MG, Scahill L, Tierney E et al. Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. Pharmacogenomics J 2014; 14: 295–302.
Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 2007; 32: 1011–1020.
Farrell SM, Tunbridge EM, Braeutigam S, Harrison PJ . COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol Psychiatry 2012; 71: 538–544.
Giakoumaki SG, Roussos P, Bitsios P . Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacology 2008; 33: 3058–3068.
Ashare RL, Wileyto EP, Ruparel K, Goelz PM, Hopson RD, Valdez JN et al. Effects of tolcapone on working memory and brain activity in abstinent smokers: a proof-of-concept study. Drug Alcohol Depend 2013; 133: 852–856.
Abi-Dargham A, Laruelle M . Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005; 20: 15–27.
Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999; 20: 612–627.
Weickert TW, Goldberg TE, Mishara A, Apud JA, Kolachana BS, Egan MF et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004; 56: 677–682.
Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004; 161: 1798–1805.
Bosia M, Zanoletti A, Spangaro M, Buonocore M, Bechi M, Cocchi F et al. Factors affecting cognitive remediation response in schizophrenia: the role of COMT gene and antipsychotic treatment. Psychiatry Res 2014; 217: 9–14.
Woodward ND, Jayathilake K, Meltzer HY . COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007; 90: 86–96.
Mata I, Arranz MJ, Staddon S, Lopez-Ilundain JM, Tabares-Seisdedos R, Murray RM . The high-activity Val allele of the catechol-O-methyltransferase gene predicts greater cognitive deterioration in patients with psychosis. Psychiatr Genet 2006; 16: 213–216.
Rebollo-Mesa I, Picchioni M, Shaikh M, Bramon E, Murray R, Toulopoulou T . COMT (Val(158/108)Met) genotype moderates the impact of antipsychotic medication on verbal IQ in twins with schizophrenia. Psychiatr Genet 2011; 21: 98–105.
Arts B, Simons CJ, Drukker M, van Os J . Antipsychotic medications and cognitive functioning in bipolar disorder: moderating effects of COMT Val108/158 Met genotype. BMC psychiatry 2013; 13: 63.
Mueller EM, Makeig S, Stemmler G, Hennig J, Wacker J . Dopamine effects on human error processing depend on catechol-O-methyltransferase VAL158MET genotype. J Neurosci 2011; 31: 15818–15825.
Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21: RC121.
Ghahremani DG, Lee B, Robertson CL, Tabibnia G, Morgan AT, De Shetler N et al. Striatal dopamine D(2)/D(3) receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans. J Neurosci 2012; 32: 7316–7324.
Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, McInerney-Leo A, Nussbaum R et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 2005; 8: 594–596.
Kayser AS, Allen DC, Navarro-Cebrian A, Mitchell JM, Fields HL . Dopamine, corticostriatal connectivity, and intertemporal choice. J Neurosci 2012; 32: 9402–9409.
Apud JA, Weinberger DR . Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors. CNS Drugs 2007; 21: 535–557.
Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002; 22: 3708–3719.
Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385: 634–636.
Floresco SB . Prefrontal dopamine and behavioral flexibility: shifting from an "inverted-U" toward a family of functions. Front Neurosci 2013; 7: 62.
Ryan SG . Regression to the truth: replication of association in pharmacogenetic studies. Pharmacogenomics 2003; 4: 201–207.
Bakker PR, van Harten PN, van Os J . Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008; 13: 544–556.
Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006; 314: 1930–1933.
Roussos P, Giakoumaki SG, Bitsios P . Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism. Biol Psychiatry 2009; 66: 997–1004.
Zhao QZ, Liu BC, Zhang J, Wang L, Li XW, Wang Y et al. Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study. Psychiatr Genet 2012; 22: 298–299.
Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH et al. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J 2009; 9: 311–318.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Schacht, J. COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review. Pharmacogenomics J 16, 430–438 (2016). https://doi.org/10.1038/tpj.2016.43
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2016.43